Through the Line: Packaging and Processing
This podcast explores innovations and information across the packaging and processing landscape, from topics impacting consumer packaged goods and healthcare packaging, to the latest technologies in food processing operations. Join us for the latest insights, trends, and strategies shaping packaging and processing today.
For Mundo Expo Pack content go to: https://vocesdesdelalinea.buzzsprout.com
Content hosted by Packaging World, ProFood World, and Healthcare Packaging.
Through the Line: Packaging and Processing
Eye Drop Recall Exposes Gaps in Sterility Assurance: Healthcare Packaging
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
How do the sterility assurance gaps reflect broader challenges in medical device and pharmaceutical packaging compliance?
More than 3.1 million bottles of lubricating eye drops were recalled because products weren't properly tested, meaning sterility couldn't be verified. However, passing a sterility test doesn’t guarantee that a whole batch of product is sterile. It only confirms that no microbes were present in the sample.
This is an AI-generated podcast episode. Read the full featured article on Healthcare Packaging.
Welcome to Through the Line, a podcast exploring innovations and information across the packaging and processing landscape. From topics impacting consumer packaged goods in healthcare packaging to the latest technologies in food processing operations.
SPEAKER_00Hi, Liz Cunio here, editor-in-chief of healthcare packaging. What follows is an AI-generated podcast from a recent article on our site. The article is about a major eyedrop recall. Listen in to learn why more than three million bottles of eyedrops have been pulled from the shelves and why this highlights a larger problem in the industry.
SPEAKER_03This deep dive explores the critical sterility standards and comprehensive manufacturing protocols required in the pharmaceutical industry, utilizing a recent massive eyedrop recall to highlight the essential role of robust processing controls and packaging integrity.
SPEAKER_02Absolutely.
SPEAKER_03Welcome everyone to our deep dive into the source text. Imagine a microscopic variance in a ceiling plate on your packaging line, something entirely invisible to the naked eye. Uh-huh. Yet that tiny fraction of a millimeter of misalignment that's literally enough to invalidate a multimillion dollar clean room process, trigger a massive national recall and ultimately threaten the vision of a million consumers.
SPEAKER_02It's terrifying when you really think about the scale of it.
SPEAKER_03Okay, let's unpack this. Because when the processing and packaging systems you operate experience a failure, the consequences, well, they aren't merely internal logistical headaches, right? Right.
SPEAKER_02It's not just a bad day at the plant.
SPEAKER_03Exactly. They ripple out immediately and devastatingly into the public health sector. And we saw this exact scenario play out starkly with the March 3, 2026 recall.
SPEAKER_02Oh, yeah, the KC Pharmaceuticals recall.
SPEAKER_03Basically, baseline sterility could no longer be verified. There was this whole cascade of testing failures, which resulted in the staggering removal of over 3.1 million bottles of lubricating eye drops from retail shelves.
SPEAKER_023.1 million bottles. That is just, it's a massive volume.
SPEAKER_03It really is. And that single manufacturing point of failure compromised eight specific production lines. Just to give you an idea of the scope, they pulled dry eye relief eye drops, artificial tears, sterile lubricant eye drops, and sterile eye drops original formula, sterile eye drops redness lubricant, eye drops advanced relief, ultra-lubricating eye drops, sterile eye drops AC, and the sterile eye drops soothing tears.
SPEAKER_02And, you know, the sheer volume there, that 3.1 million, it really reveals the hidden vulnerabilities inherent in our decentralized pharmaceutical supply chains.
SPEAKER_03Right, because they don't just sit in one place.
SPEAKER_02Exactly. As professionals managing these massive production runs, you understand that these compromised batches, they don't just sit in the single warehouse under one easily identifiable label.
SPEAKER_03Yeah, they get everywhere.
SPEAKER_02They do. They were distributed rapidly and aggressively to major retailers nationwide. The affected products were rebranded, seamlessly integrating into the market under 12 different company names.
SPEAKER_03So if I'm a consumer, I don't even know it's Casey Pharmaceuticals.
SPEAKER_02Nope. They hit the consumer shelves, branded as Top Care, Best Choice, Good Sense, Rugby, Leader, Good Neighbor Pharmacy.
SPEAKER_03Oh, wow.
SPEAKER_02Yeah. Quality choice, Val merchandisers, Geary Care, Walgreens, CVS, and Kroger.
SPEAKER_03That's basically every major pharmacy and grocery chain.
SPEAKER_02Exactly. This vast level of market penetration effectively masks the origin of the risk from the end consumer. A report from CNN isolates the severe medical stakes involved here.
SPEAKER_03Which are pretty high, I imagine.
SPEAKER_02Oh, extremely high.
SPEAKER_03Yeah.
SPEAKER_02Because of the sheer size of the distribution network, over a million people may have been directly exposed to the defect.
SPEAKER_03A million people.
SPEAKER_02Yeah. And the danger is acute because non-sterile eye drops, they can harbor various highly resilient forms of bacteria and fungus.
SPEAKER_03And you're putting that directly into your eye.
SPEAKER_02Right. When a consumer introduces these pathogens directly into the eye, they are entirely bypassing the body's natural epidermal defenses. I mean, the skin usually protects us.
SPEAKER_03Right, but the eye doesn't have that layer.
SPEAKER_02Exactly. The eye is a highly sensitive vascular organ. So these localized microbial introductions, they can rapidly escalate into severe, vision-threatening, and potentially systemic infections.
SPEAKER_03Man, looking at the massive scale of that distribution network, it really brings up a highly logical question regarding end-of-line verification. I mean, it's one that teams on the processing floor encounter all the time. Sure. The Food and Drug Administration strictly mandates sterility testing on final products? Yes, they do. So if you are operating a facility and your final batch passes that FDA sterility test, how does a compromised non-sterile product ever clear the loading dock to reach those retailers?
SPEAKER_02It's a great question.
SPEAKER_03Right. From a conventional quality assurance perspective, a pass test at the end of the line kind of implies the product is perfectly safe and verified for consumer use.
SPEAKER_02Yeah, and that assumption that a final test guarantees batch sterility is a profound and dangerous misconception in pharmaceutical manufacturing.
SPEAKER_03Really? A dangerous misconception.
SPEAKER_02Absolutely. Passing a sterility test on a final product only proves one highly specific fact. It just means there were no viable microbes present in the specific representative sample tested at that exact moment.
SPEAKER_03Oh, I see. So it's just that one bottle.
SPEAKER_02Yes. It categorically does not apply a blanket guarantee of sterility across the remaining millions of units in the production badge.
SPEAKER_03That makes sense, actually.
SPEAKER_02And the FDA recognizes this statistical limitation. That's why they operate on a much more rigorous standard known as the sterility assurance level, or SAL. For these types of pharmaceutical products, the FDA requires a sell of less than a one in a million probability of a non-sterile unit.
SPEAKER_03One in a million.
SPEAKER_02What's fascinating here is the mathematical impossibility of achieving this standard through reactive final testing alone.
SPEAKER_03Why is it impossible? Just because of the math.
SPEAKER_02Well, sterile testing is inherently destructive. You must break the final packaging seal, extract the product, and culture it in a laboratory setting to check for microbial growth.
SPEAKER_03Oh, so you destroy the product to test it.
SPEAKER_02Exactly. To statistically prove a one in a million probability of failure through testing alone, you would have to destructively test virtually every single unit you manufacture.
SPEAKER_03Which means you'd have nothing left to sell.
SPEAKER_02Precisely. Yeah. You would consume your entire inventory, leaving zero product left to ship to the retailers.
SPEAKER_03That's quite the paradox. So that destructive testing paradox means the burden of proof, it basically shifts entirely to the manufacturing process itself rather than relying on a final checkpoint.
SPEAKER_02You hit the nail on the head.
SPEAKER_03You know, it's helpful to think about this using a structural analogy. Achieving that one in a million sterility assurance level, it's like designing a high security vault.
SPEAKER_02Ooh, I like that.
SPEAKER_03Right. You don't simply install a heavy steel door at the end of a corridor and assume the contents are safe.
SPEAKER_02Because a single door is a single point of failure.
SPEAKER_03Exactly. Instead, you design a comprehensive layered architectural system. You mandate rigorous background checks on the guards monitoring the facility. Right. You install specialized climate controls so the locking mechanisms don't degrade or rust over time. You implement constant overlapping camera monitoring across every inch of the perimeter.
SPEAKER_02The security is built into the environment long before the door is closed.
SPEAKER_03Right. The security is inextricably built into the environment. So how does that translate to the clean room?
SPEAKER_02Well, the vault analogy provides a really solid foundation for understanding the FDA's holistic approach. But we have to take it a step further to match the physical realities of an aseptic processing floor.
SPEAKER_03Okay, how so?
SPEAKER_02A vault is essentially static, right? Whereas a clean room environment is aggressively dynamic, it utilizes highly engineered airflows to actively repel microscopic intruders.
SPEAKER_03That makes sense. Active defense rather than passive.
SPEAKER_02Exactly. The source material outlines specific processing mandates required by the FDA that function as the active layers of this security system.
SPEAKER_03Let's walk through those layers.
SPEAKER_02Sure. The foundation begins with validated sterilization processes. You know from operating these systems that running a sterilization cycle isn't just about throwing heat or gas at a product and hoping for lethality.
SPEAKER_03Right, you can't just guess.
SPEAKER_02Exactly. The chosen method must be scientifically proven, heavily documented, and validated to consistently achieve that one in a million SAL under rigorous real-world operational parameters.
SPEAKER_03So taking into account things like load density and thermal mass.
SPEAKER_02Yes. And the specific thermal resistance of the packaging materials. Everything has to be calculated.
SPEAKER_03Aaron Powell But executing a validated sterilization cycle requires a controlled environment to house it in the first place, which brings us directly to robust environmental controls.
SPEAKER_02Aaron Powell All right, the clean rooms.
SPEAKER_03Yeah. And this goes far beyond standard industrial air conditioning. We are talking about highly engineered HVAC systems managing precise air changes per hour.
SPEAKER_02Aaron Powell It's incredibly precise.
SPEAKER_03Aaron Powell And maintaining specific pressure cascades between rooms so that if a door opens, the positive pressure forcefully pushes air out, preventing cross-contamination from entering the aseptic core.
SPEAKER_02Aaron Powell That positive pressure is absolutely critical.
SPEAKER_03It really is. It also involves utilizing terminal HEPA filtration to physically trap airborne particulates in microorganisms before they ever enter the processing area.
SPEAKER_02Aaron Powell Exactly.
SPEAKER_03However, I want to challenge the assumption that a well-designed clean room just remains clean automatically.
SPEAKER_02Oh, it definitely doesn't.
SPEAKER_03Right. Even with positive pressure and HEPA filtration, operations cannot assume the environment remains static, which necessitates routine monitoring and testing.
SPEAKER_02Continuous vigilance.
SPEAKER_03Yeah. You have to continuously execute microbiological monitoring of the ambient air, the processing surfaces, the equipment, and the personnel.
SPEAKER_02And why is that continuous surveillance so important?
SPEAKER_03Because it detects transient contamination events or rising trends in the facility's microbial baseline before those pathogens physically reach the product line.
SPEAKER_02Aaron Powell That's a great point. And that continuous surveillance is heavily reliant on the efficacy of validated cleaning and maintenance procedures.
SPEAKER_03Right. Because standard sanitization isn't going to cut it.
SPEAKER_02Not even close. Standard industrial sanitization is entirely insufficient for pharmaceutical processing. Equipment and facilities must be maintained under validated protocols specifically designed to prevent the buildup of bioburden.
SPEAKER_03And if you leave bio burden unchecked.
SPEAKER_02If bioburden is left unchecked on a processing surface, it can rapidly develop into biofilms.
SPEAKER_03Ah, biofilms. Those are notoriously tough to deal with.
SPEAKER_02They are. As you likely manage on the floor, biofilms are complex structured communities of bacteria that excrete a protective polymeric matrix.
SPEAKER_03A protective matrix, so it's like a shield.
SPEAKER_02Exactly like a shield. This matrix acts as a highly resilient physical barrier, allowing the bacteria beneath it to survive aggressive chemical sanitizers and even certain sterilization cycles. Yeah, so preventing this biofilm formation is the primary purpose behind these exhaustive cleaning validations.
SPEAKER_03And I imagine the greatest unpredictable threat to that meticulously cleaned environment, despite rigorous sanitization, is actually the human element.
SPEAKER_02Oh, absolutely. Humans are the dirtiest things in the clean room.
SPEAKER_03Which necessitates strict personnel training and hygiene. I mean, a human being shedding microscopic skin cells and respiratory droplets, that is the highest contamination risk inside any aseptic processing area.
SPEAKER_02By far.
SPEAKER_03This is precisely why staff undergo such rigorous training in aseptic techniques and those really complex gowning procedures.
SPEAKER_02It takes a long time just to learn how to put the suit on correctly.
SPEAKER_03Right, because the gowning is not just a clean uniform, it's a wearable, full-body containment system meticulously designed to trap human bio burden and prevent it from disrupting the sterile laminar airflow of the clean room.
SPEAKER_02And managing all of these highly dynamic variables, the air, the cleaning, the personnel, it requires absolute traceability, which is why operators must document all processes and deviations.
SPEAKER_03The paperwork.
SPEAKER_02The endless paperwork, yes. But in the realm of regulatory compliance, comprehensive documentation is quite literally as critical as the physical process itself.
SPEAKER_03Because if it isn't documented, it didn't happen.
SPEAKER_02Exactly. Every single parameter, from the temperature of the water for injection to the differential pressure of the clean room corridors, must be recorded in real time.
SPEAKER_03And if something is off?
SPEAKER_02If a parameter falls outside the validated range, that deviation must be thoroughly investigated and justified. This unbroken documentation trail is the only legal and scientific proof a facility has that sterility assurance was maintained.
SPEAKER_03Throughout the entire batch run.
SPEAKER_02Right. Without it, the FDA inherently assumes the batch is adulterated, regardless of what the final sterility test indicates.
SPEAKER_03Yeah. Here's where it gets really interesting, especially for those of you operating the packaging lines.
SPEAKER_02Oh, absolutely.
SPEAKER_03We have just explored an incredibly synchronized, multimillion dollar effort involving engineered clean rooms, biofilm prevention, and intense personnel containment protocols.
SPEAKER_02A massive undertaking.
SPEAKER_03Yeah. However, every ounce of that processing effort and all of that massive investment in the clean room environment is instantly nullified if the actual sterilization method fails to penetrate the product or if the final packaging seal is structurally compromised.
SPEAKER_02It all comes down to the packaging.
SPEAKER_03It does. The entire manufacturing ecosystem is entirely dependent on the final execution of the packaging sector to permanently lock in that sterility.
SPEAKER_02The responsibility absolutely pivots to the efficacy of the sterilization techniques and the physical containment provided by the packaging materials.
SPEAKER_03So how does the FDA regulate that final step?
SPEAKER_02Well, the FDA outlines four primary approved sterilization methods. For industry professionals, the selection and validation of these methods is an ongoing engineering challenge.
SPEAKER_03Balancing maximum lasality with material compatibility.
SPEAKER_02Precisely. The first method is steam sterilization, which utilizes pressurized high-temperature steam.
SPEAKER_03Which sounds straightforward, but probably isn't.
SPEAKER_02Not at all. While highly effective, achieving saturated steam penetration through complex polymer packaging or dense liquid loads requires meticulous cycle development.
SPEAKER_03So you don't melt the package.
SPEAKER_02Right, to prevent package deformation, melting, or dangerous moisture retention.
SPEAKER_03Okay, what's the second method?
SPEAKER_02The second is ethylene oxide, or EO gas sterilization. This is vital for materials that simply cannot withstand the high heat of steam.
SPEAKER_03Oh, okay. But gas brings its own issues.
SPEAKER_02It does. EO validation is highly complex. You must ensure the gas deeply penetrates the packaging to achieve lethality while simultaneously validating exhaustive aeration parameters.
SPEAKER_03Aeration, you mean like off-gassing.
SPEAKER_02Exactly. You have to ensure no toxic residual gas remains trapped within the polymer matrix of the container before it reaches the consumer.
SPEAKER_03Wow. And I imagine radiation and filtration present their own unique sets of material challenges on the line.
SPEAKER_02They absolutely do.
SPEAKER_03Like when utilizing radiation, typically gamma rays or electron beams, you are relying on the energy to penetrate the packaging and permanently disrupt the microbial DNA within the product.
SPEAKER_02Aaron Powell Which is very effective at killing microbes.
SPEAKER_03Sure, but operations must concurrently validate that the radiation dosage does not degrade the tensile strength, alter the color, or compromise the chemical stability of the plastic container itself over its entire shelf life.
SPEAKER_02Right. You don't want brittle bottles.
SPEAKER_03Exactly. And for liquid products that are highly sensitive to both heat and radiation, manufacturers utilize filtration.
SPEAKER_02That's a fascinating process.
SPEAKER_03Yeah. You are relying on microscopic filter membranes to physically screen out pathogens before the liquid enters the sterile container.
SPEAKER_02But how do you know the filter didn't break?
SPEAKER_03Well, that process relies heavily on continuous bubble point testing to ensure the filter membrane has not suffered a micro-tear during the pressurized run.
SPEAKER_02Precisely. And to scientifically verify that these varied sterilization cycles actually achieve the required lethality at a microscopic level, operations rely heavily on sterilization indicators.
SPEAKER_03Like the little color changing strips.
SPEAKER_02Yeah, manufacturers utilize chemical indicators, which provide critical visual proof through a distinct color change. That the product was physically exposed to the correct parameters, like the proper temperature or gas concentration.
SPEAKER_03But that doesn't prove things actually died, right?
SPEAKER_02Right. And that's why, more importantly, operations utilize biological indicators.
SPEAKER_03Okay, what are those?
SPEAKER_02These contain highly resistant, standardized bacterial spores, such as Geobacillus sterothermophilus.
SPEAKER_03That is quite the name.
SPEAKER_02It is. By placing these resilient spores in the most difficult to sterilize locations within a product load, running the cycle and then proving the spores have been completely destroyed, you physically demonstrate that the cycle was robust enough to kill the most resilient pathogens known.
SPEAKER_03Oh wow. So if it kills the hardest thing to kill, it killed everything else.
SPEAKER_02Exactly. This successfully validates the lethality for the rest of the commercial batch.
SPEAKER_03That biological verification is the definitive proof of lethality, but it really shifts the spotlight squarely to the structural integrity of the final product.
SPEAKER_02It really does.
SPEAKER_03Because the source material defines the ultimate responsibility of the packaging sector quite clearly, the packaging must maintain that achieved sterility until the absolute point of use by the consumer.
SPEAKER_02That is the ultimate goal.
SPEAKER_03Yeah. Once that liquid is sterilized, it becomes an incredibly vulnerable asset. The primary container closure system is the only physical barrier separating that sterile, purified environment from the non-sterile, highly contaminated outside world.
SPEAKER_02And maintaining that barrier is arguably the most critical and continuous physical challenge in pharmaceutical manufacturing.
SPEAKER_03How do they even test that constantly?
SPEAKER_02It requires rigorously validated sealing processes and exhaustive continuous packaging integrity testing, such as vacuum decay or dye ingress testing.
SPEAKER_03Vacuum decay.
SPEAKER_02You must verify that the seal is completely impermeable to microbial ingress under various physical stresses.
SPEAKER_03Right, because things get bumped around in transit.
SPEAKER_02Exactly. Think about it. If a sealing plant on your packaging line falls out of alignment by a fraction of a millimeter due to mechanical wear.
SPEAKER_03Or um if a specific lot of high-density polyethylene bottles contains microscopic variations in the thread depth due to molding temperature fluctuations.
SPEAKER_02Then the container closure seal is compromised.
SPEAKER_03It's that sensitive.
SPEAKER_02Yes. A micro leak allows microbial ingress from the ambient environment during shipping, warehousing, or retail display.
SPEAKER_03And if that happens, the whole process is ruined.
SPEAKER_02Completely ruined. If that seal fails, the entire unbroken chain of custody we just discussed, the HEPA filtration, the aseptic gowning, the biological indicators, it's completely invalidated.
SPEAKER_03The barrier is broken.
SPEAKER_02The barrier is broken. This is exactly how an event like the 3.1 million bottle recall occurs. A failure in the validation of the packaging seal results in the sudden, terrifying inability to verify the sterility of millions of units already integrated into the daily routines of the public.
SPEAKER_03So what does this all mean for the processing and packaging professionals operating these complex systems shift after shift?
SPEAKER_02Well, it's a huge responsibility.
SPEAKER_03It really is. It means that sterility in pharmaceutical manufacturing is never a static end-of-line checkpoint. It is not a final box to be checked off by a quality assurance team at the loading dock. Not at all. It's a continuous, relentless, multi-layered operational discipline. It spans from the highly complex thermodynamic calculations of your sterilization cycles, passes through the careful, active management of clean room air pressure cascades and personnel hygiene routines.
SPEAKER_02All those layers.
SPEAKER_03Yeah, and extends all the way down to the microscopic, validated precision of the final tamper evidence seal on a consumer package. Every single stage is an active, necessary barrier.
SPEAKER_02If we connect this to the bigger picture, it reinforces the absolute gravity of your daily operations on the processing floor.
SPEAKER_03Absolutely.
SPEAKER_02The strict, heavily regulated, and exhaustively documented protocols you follow are not simply bureaucratic hurdles imposed by the FDA.
SPEAKER_03Even if they feel like it sometimes.
SPEAKER_02Right. Even if they feel tedious. Your precise execution of equipment calibration, your rapid analytical response to environmental monitoring deviations, and your absolute refusal to compromise on ceiling validation parameters, those are the exact mechanisms standing between public safety and a massive million pension infection event.
SPEAKER_03The stakes couldn't be higher.
SPEAKER_02They really couldn't. The integrity of the global healthcare supply chain and the fundamental health of the public rely entirely on the exactness of your engineering and your daily vigilance.
SPEAKER_01Thank you for listening to Through the Line Packaging and Processing. You can listen to more episodes on all streaming platforms. Be sure to visit us at packworld.com, profoodworld.com, and healthcarepackaging.com for more packaging and processing news. This podcast was edited by Bree Guns.
